RESUMEN
With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing. Representatives from the North American Neuroendocrine Tumor Society and the Society of Nuclear Medicine and Molecular Imaging collaborated to develop a practical consensus guideline for the administration of 177Lu-DOTATATE. In this paper, we discuss patient screening, maintenance somatostatin analog therapy requirements, treatment location and room preparation, drug administration, and patient release as well as strategies for radiation safety, toxicity monitoring, management of potential complications, and follow-up. Controversies regarding the role of radiation dosimetry are discussed as well. This document is designed to provide practical guidance on how to safely treat patients with this therapy.
Asunto(s)
Tumores Neuroendocrinos/radioterapia , Medicina Nuclear , Octreótido/análogos & derivados , Compuestos Organometálicos/uso terapéutico , Receptores de Somatostatina/metabolismo , Sociedades Médicas/normas , Médula Ósea/efectos de la radiación , Humanos , Riñón/efectos de la radiación , Octreótido/administración & dosificación , Octreótido/efectos adversos , Octreótido/uso terapéutico , Compuestos Organometálicos/administración & dosificación , Compuestos Organometálicos/efectos adversos , Órganos en Riesgo/efectos de la radiación , Radiometría , Estándares de Referencia , SeguridadRESUMEN
Insulin pumps are not typically assessed for malfunction after exposure to significant radiation. We assessed an insulin pump kept for 48 hours on a patient on hemodialysis who required radioactive iodine ablation treatment for thyroid cancer. On download inspection, the pump showed normal function.
